Success Metrics

Active Trials
4(57%)

Phase Distribution

Ph phase_3
2
29%
Ph phase_2
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Other(2)

Detailed Status

Recruiting3
Not yet recruiting1
Suspended1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

not_yet_recruiting114%
suspended114%
unknown114%
recruiting343%
active_not_recruiting114%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_3

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706
recruitingphase_3

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

NCT06564324
active_not_recruitingphase_2

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811
unknown

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874
not_yet_recruiting

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

NCT07199010
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07154706Phase 3

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Recruiting
NCT06564324Phase 3

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Recruiting
NCT04919811Phase 2

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Active Not Recruiting
NCT06841874

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Unknown
NCT07199010

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Not Yet Recruiting
NCT07008287

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Recruiting
NCT06214793Phase 2

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Suspended

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7